# Renal Impairment Study of Empagliflozin (BI10773) in Japanese Patients With Type 2 Diabetes

> **NCT01581658** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 32 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** BI10773
- **DRUG:** BI10773
- **DRUG:** BI10773
- **DRUG:** BI10773

## Key facts

- **NCT ID:** NCT01581658
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04-01
- **Primary completion:** 2012-11-01
- **Final completion:** 2012-11-01
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2017-08-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01581658

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01581658, "Renal Impairment Study of Empagliflozin (BI10773) in Japanese Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01581658. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*